Following a full submission
AWMSG advice |
|||
| Status: Recommended with restrictions | |||
5-aminolaevulinic acid (Ameluz®) is recommended as an option for restricted use within NHS Wales for the treatment of actinic keratosis of mild to moderate severity on the face and scalp (Olsen grade 1 to 2) and of field cancerization in adults. 5-aminolaevulinic acid (Ameluz®) is recommended only when photodynamic therapy is considered appropriate. |
|||
|
|||
Medicine details |
|||
| Medicine name | 5-aminolaevulinic acid (Ameluz®) | ||
| Formulation | 78 mg/g gel | ||
| Reference number | 1074 | ||
| Indication | Treatment of actinic keratosis of mild to moderate severity on the face and scalp (Olsen grade 1 to 2) and of field cancerization in adults |
||
| Company | Biofrontera | ||
| BNF chapter | Skin | ||
| Assessment type | Full | ||
| Status | Recommended with restrictions | ||
| Advice number | 2713 | ||
| NMG meeting date | 11/09/2013 | ||
| AWMSG meeting date | 16/10/2013 | ||
| Ratification by Welsh Government | 02/12/2013 | ||
| Date of issue | 03/12/2013 | ||
| Date of last review | 02/02/2017 | ||